ReviewGastroenterology2015
Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.
Review in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Causal immune-inflammation mapping of the GERD-Barrett-adenocarcinoma cascade identifies FGF19-HLA-DR⁺ T-cell axis driving esophagogastric junction metaplasia.Journal of translational medicine · 2026Article
- Pathogenesis of Barrett's Esophagus: Evolving and Emerging Mechanisms.Gastrointestinal endoscopy clinics of North America · 2026Review
- Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells.Gastroenterology · 2025Article
- Article
- Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.Visceral medicine · 2022Review
- Clonal Transitions and Phenotypic Evolution in Barrett's Esophagus.Gastroenterology · 2022Article
- The SpaTemp cohort: 168 nondysplastic Barrett's esophagus surveillance patients with and without progression to early neoplasia to evaluate the distribution of biomarkers over space and time.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2021Article
- Drivers of Esophageal Adenocarcinoma and Opportunities for Cancer Interception.Cellular and molecular gastroenterology and hepatology · 2021Article
- Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.Clinical and translational gastroenterology · 2020Article
- The Y-chromosome F haplogroup contributes to the development of Barrett's esophagus-associated esophageal adenocarcinoma in a white male population.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2020Article
- Cancer-Associated Mutations but No Cancer: Insights into the Early Steps of Carcinogenesis and Implications for Early Cancer Detection.Trends in cancer · 2019Review
- UGT2B17 and miR-224 contribute to hormone dependency trends in adenocarcinoma and squamous cell carcinoma of esophagus.Bioscience reports · 2019Article
- Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice.Digestive diseases and sciences · 2018Review
- Chronology of gastrointestinal cancer.Surgery today · 2018Review
- Evolution of Premalignant Disease.Cold Spring Harbor perspectives in medicine · 2017Review
- Quantitation of spatial and temporal variability of biomarkers for Barrett's Esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2017Article
- Molecular subtypes in cancers of the gastrointestinal tract.Nature reviews. Gastroenterology & hepatology · 2017Review
- Editorial on role of p53 in esophageal cancer from a meta-analysis of 16 studies by FisherJournal of thoracic disease · 2017Article
- Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective.Cellular and molecular gastroenterology and hepatology · 2017Review
- Screening and Preventive Strategies in Esophagogastric Cancer.Surgical oncology clinics of North America · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Beginning in the 1980s, an alarming rise in the incidence of esophageal adenocarcinoma (EA) led to screening of patients with reflux to detect Barrett's esophagus (BE) and surveillance of BE to detect early EA. This strategy, based on linear progression disease models, resulted in selective detection of BE that does not progress to EA over a lifetime (overdiagnosis) and missed BE that rapidly progresses to EA (underdiagnosis). Here we review the historical thought processes that resulted in this undesired outcome and the transformation in our understanding of genetic and evolutionary principles governing neoplastic progression that has come from application of modern genomic technologies to cancers and their precursors. This new synthesis provides improved strategies for prevention and early detection of EA by addressing the environmental and mutational processes that can determine "windows of opportunity" in time to detect rapidly progressing BE and distinguish it from slowly or nonprogressing BE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.